Otonomy, Inc
San Diego, United States
11 employees
Post-IPO Equity
Total: $498.01M
Biopharma, Biotechnology +1
General Information
San Diego, United States
BounceWatch is an independent company data service, not affiliated with Otonomy, Inc. To contact Otonomy, Inc, visit otonomy.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
Discover More
United States Market
Biopharma
About Otonomy, Inc
Taxonomy: biopharmaceutical, drug delivery technology, ear disorders, innovative therapeutics, sustained drug exposure, patent estate, Ménière’s disease, hearing loss, tinnitus, medical research, innovation, pharmaceutical development, ear health
Funding Rounds & Investors (10)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Post IPO Equity | $34.70M | - |
|
07 Apr 2021 |
| Post IPO Equity | $69.10M | - |
|
09 Jul 2020 |
| Post IPO Equity | $40.00M | - |
|
01 Aug 2019 |
| Post IPO Equity | $115.00M | - |
|
06 Jan 2016 |
| Post IPO Equity | $85.78M | - |
|
22 Jan 2015 |
| Series D | $49.00M | 10 |
|
30 Apr 2014 |
| Series C | $45.90M | 8 |
|
04 Sep 2013 |
| Venture Round | $10.04M | - |
|
02 Sep 2010 |
| Series B | $38.50M | 4 |
|
30 Aug 2010 |
| Series A | $10.00M | 1 |
|
11 Jun 2010 |
Otonomy, Inc Alternatives & Competitors
View All Alternatives
Pioneering RNA-targeted therapies with rapid LNA-based drug development for diverse disease states.
Clinical-stage biotech developing patient-friendly drug candidates for the treatment of lysosomal st...
The Specialist in CNS Drug Development
FAQ About Otonomy, Inc
Source: BounceWatch company record for Otonomy, Inc, https://bouncewatch.com/company/otonomy-inc, updated 28 November 2024. When citing, please name BounceWatch and link this page.
